Nuclear Medicine: Page 123

DEA removes GE compound as controlled substance

By AuntMinnie.com staff writers

The U.S. Drug Enforcement Administration (DEA) has removed a compound found in GE Healthcare's DaTscan SPECT radiopharmaceutical from the schedules of the Controlled Substances Act, which means the imaging agent will be more widely available to the medical community.

September 13, 2015

Nuclear medicine market to reach $2.13B by 2020

By AuntMinnie.com staff writers

The global nuclear medicine equipment market is expected to grow at a compound annual growth rate of 3.6% over the next five years, according to a new report by market research firm MarketsandMarkets.

September 10, 2015

NorthStar, Westinghouse Electric join forces

By AuntMinnie.com staff writers

With an eye toward increasing the worldwide supply of molybdenum, NorthStar Medical Radioisotopes and nuclear energy firm Westinghouse Electric have inked a memorandum of understanding to explore the potential of producing medical radioisotopes in commercial nuclear reactors.

September 8, 2015

PET/MRI can be a boon for pediatric cancer patients

By Wayne Forrest

Young pediatric patients may benefit from FDG-PET/MRI for staging and clinically evaluating oncologic disorders, given the hybrid modality's superior soft-tissue contrast and significantly lower radiation dose, according to a study published online August 24 in Investigative Radiology.

September 8, 2015

U.S. NRC starts review of LNT radiation theory

By AuntMinnie.com staff writers

The U.S. Nuclear Regulatory Commission (NRC) is reviewing the linear no-threshold (LNT) model of the health effects of radiation and the idea that LNT should be replaced with a radiation hormesis model.

September 7, 2015

ImaginAb highlights prostate imaging trial

By AuntMinnie.com staff writers

Imaging agent developer ImaginAb is touting interim results from a phase II clinical trial of its IAB2M imaging agent for managing prostate cancer.

September 7, 2015

PET/MRI matches PET/CT for recurrent pelvic cancer

By Wayne Forrest

PET/MRI can provide high diagnostic performance for restaging gynecological cancer patients compared with FDG-PET/CT, with only slightly longer scan time and "markedly reduced" radiation exposure, according to a German study published online in the European Journal of Radiology.

September 3, 2015

Firm to develop Mo-99 without reactor

By AuntMinnie.com staff writers

California Science and Engineering of Irvine, CA, has announced that it plans to develop and produce molybdenum-99 (Mo-99) without a nuclear reactor.

September 2, 2015

Navidea scores $1.8M NIH grant

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals has received a $1.8 million grant from the U.S. National Institutes of Health (NIH) to evaluate one of its radiopharmaceuticals in Kaposi's sarcoma.

September 2, 2015

SNMMI announces fellowship recipients

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has unveiled the recipients of its 2015-2017 SNMMI Wagner-Torizuka Fellowship.

August 31, 2015

Perma-Fix completes test of Tc-99m process

By AuntMinnie.com staff writers

Perma-Fix Medical has successfully completed the scale-up of its process to produce technetium-99m (Tc-99m) from molybdenum.

August 31, 2015

NorthStar begins Mo-99 production in Mo.

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes has begun routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor facility in Columbia, MO.

August 30, 2015

Previous Page

Page 123 of 438

Next Page